Regional experience in assessing medical technology on the example of antiviral therapy for chronic hepatitis C with direct antiviral drugs

Cover Page

Cite item

Full Text

Abstract

Introduction. Such medical technology like a direct antiviral drugs for treatment for chronic hepatitis C (CHC) remains inaccessible due to high absolute cost for health care systems, lack of assessment in specific region of Russian Federation and correlation with results of used antiviral therapy options.

The purpose of the study is to determine most cost-effective option of drug provision with direct antiviral drugs for the treatment of chronic hepatitis C.

Material and methods. Based on the population of chronic hepatitis C adult patients receiving medications at expense of Moscow budget funds, was performed a pharmacoeconomic analysis of drug therapy with direct antiviral drugs.

Results. The use of new pangenotypic direct antiviral drugs for the treatment of CHC in a clinically heterogeneous population of Russian adults with 1-6 genotypes of the hepatitis C virus is economically justified. Both alternative scenarios demonstrated an advantage over the baseline scenario in the form of financial savings of 66,028,192. 45 rubles and 83,647,819.27 rubles and an increase in the number of effectively treated patients by 197 and 287 people per year, respectively.

Conclusion. An increase in the share of new direct antiviral drugs in drug supply programs will increase the efficiency of the use of financial resources and increase the availability of direct antiviral drugs, which may ultimately lead to the achievement of an epidemiological effect on a population scale.

About the authors

Ekaterina B. Kornilova

Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department

Author for correspondence.
Email: ekaterinakornilova2017@gmail.com
ORCID iD: 0000-0002-7214-4340

MD, Ph.D., leading researcher, Research Institute of Health Organization and Medical Management of Moscow Healthcare Department, Moscow, 115088, Russia.

e-mail: ekaterinakornilova2017@gmail.com

Russian Federation

Malwina Ewa Hołownia-Voloskova

Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department; Department of Experimental and Clinical Pharmacology, Medical University of Warsaw

Email: noemail@neicon.ru
ORCID iD: 0000-0002-2437-298X
Russian Federation

Elena S. Ar’Kova

Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department

Email: noemail@neicon.ru
ORCID iD: 0000-0002-0798-5493
Russian Federation

Dmitriy A. Roslik

Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department

Email: noemail@neicon.ru
ORCID iD: 0000-0002-7668-378X
Russian Federation

Evgenii A. Luchinin

Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department

Email: noemail@neicon.ru
ORCID iD: 0000-0001-6304-4594
Russian Federation

Aleksandr A. Zavyalov

Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department

Email: noemail@neicon.ru
ORCID iD: 0000-0003-1825-1871
Russian Federation

References

  1. WHO. Hepatitis C. Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c
  2. WHO. World Hepatitis Day 2020. Available at: https://www.who.int/campaigns/world-hepatitis-day/2020
  3. Rosstat. Estimate of the permanent population as of January 1, 2020 and the average for 2019. Available at: https://rosstat.gov.ru/folder/12781 (in Russian)
  4. Alter M.J., Margolis H.S., Krawczynski K., Judson F.N., Mares A., Alexander W.J., et al. The natural history of community-acquired hepatitis C in the united states. N. Engl. J. Med. 1992; 327(27): 1899–905. https://doi.org/10.1056/NEJM199212313272702
  5. Shiff E.R. The alcoholic patient with Hepatitis C Virus infection. Am. J. Med. 1999; 107(6B): 10–5. https://doi.org/10.1016/S0002-9343(99)00393-9.
  6. Armstrong G.L., Alter M.J., McQuillan G.M., Margolis H.S. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology. 2000; 31(3): 777–82. https://doi.org/10.1002/hep.510310332.
  7. Chung R.T. AASLD-IDSA HCV Guidance Panel. Hepatitis C guidance 2018 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis c virus infection. Clin. Infect. Dis. 2018; 67(10):1477–92. https://doi.org/10.1093/cid/ciy585
  8. EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatology. 2020; 73(5): 1170–218. https://doi.org/10.1016/j.jhep.2020.08.018.
  9. WHO. Global health sector strategy on viral hepatitis, 2016–2021. Available at: http://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf?sequence=1
  10. Berden F.A., Aaldering B.R., Groenewoud H., IntHout J., Kievit W., Drenth J.P. Identification of the best direct-acting antiviral regimen for patients with hepatitis C Virus genotype 3 infection: a systematic review and network meta-analysis. Clin. Gastroenterol. Hepatol. 2017; 15(3): 349–59. https://doi.org/10.1016/j.cgh.2016.10.034
  11. Majumdar A., Kitson M.T., Roberts S.K. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment. Pharmacol. Ther. 2016; 43(12): 1276–92. https://doi.org/10.1111/apt.13633
  12. Poordad F., Schiff E.R., Vierling J.M., Landis C., Fontana R.J., Yang R., et al. Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence. Hepatology. 2016; 63(5): 1493–505. https://doi.org/10.1002/hep.28446
  13. Wei L., Jia J.D., Wang F.S., Niu J.Q., Zhao X.M., Mu S., et al. Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL study. J. Gastroenterol. Hepatol. 2019; 34(1): 12–21. https://doi.org/10.1111/jgh.14509
  14. Kwo P., Gane E.J., Peng C.Y., Pearlman B., Vierling J.M., Serfaty L., et al. Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology. 2017; 152(1): 164–75. https://doi.org/10.1053/j.gastro.2016.09.045
  15. Abergel A., Asselah T., Mallat A., Chanteranne B., Faure F., Larrey D., et al. Phase 3, multicenter open-label study to investigate the efficacy of elbasvir and grazoprevir fixed-dose combination for 8 weeks in treatment-naive, HCV GT1b-infected patiénts, with non-severe fibrosis. Liver Int. 2020; 40(8): 1853–9. https://doi.org/10.1111/liv.14502
  16. Huang C.F., Hung C.H., Cheng P.N., Bair M.J., Huang Y.H., Kao J.H., et al. An open-label, randomized, active-controlled trial of 8 versus 12 weeks of elbasvir/grazoprevir for treatment-naive patients with chronic hepatitis C genotype 1b infection and mild fibrosis (EGALITE Study): impact of baseline viral loads and NS5A resistance-associated substitutions. J. Infect. Dis. 2019; 220(4): 557–66. https://doi.org/10.1093/infdis/jiz154
  17. Zeuzem S., Serfaty L., Vierling J., Cheng W., George J., Sperl J., et al. The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection. J. Gastroenterol. 2018; 53(5): 679–88. https://doi.org/10.1007/s00535-018-1429-3
  18. Djambazov S., Slavchev G., Encheva M., Mitova R., Vekov T. Comparative effectiveness of pan-genotypic therapies for the treatment of patients with hepatitis C virus infection in Bulgaria. J. Comp. Eff. Res. 2019; 8(7): 455–9. https://doi.org/10.2217/cer-2018-0143
  19. Zeuzem S., Foster G.R., Wang S., Asatryan A., Gane E., Feld J.J., et al. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N. Engl. J. Med. 2018; 378(4): 354–69. https://doi.org/10.1056/NEJMoa1702417
  20. Takehara T., Sakamoto N., Nishiguchi S., Ikeda F., Tatsumi T., Ueno Y., et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J. Gastroenterol. 2019; 54(1): 87–95. https://doi.org/10.1007/s00535-018-1503-x
  21. Ghany M.G., Morgan T.R. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020; 71(2): 686–721. https://doi.org/10.1002/hep.31060
  22. Foster G.R., Afdhal N., Roberts S.K., Bräu N., Gane E.J., Pianko S., et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N. Engl. J. Med. 2015; 373(27): 2608–17. https://doi.org/10.1056/NEJMoa1512612
  23. Forns X., Lee S.S., Valdes J., Lens S., Ghalib R., Aguilar H., et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect. Dis. 2017; 17(10): 1062–8. https://doi.org/10.1016/S1473-3099(17)30496-6
  24. Asselah T., Kowdley K.V., Zadeikis N., Wang S., Hassanein T., Horsmans Y., et al. Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with Hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin. Gastroenterol. Hepatol. 2018; 16(3): 417–26. https://doi.org/10.1016/j.cgh.2017.09.027
  25. Kornilova E.B., Kholovnya-Voloskova M.E., Kornilov M.N., Zav’yalov A.A. Evaluation of the cost-effectiveness of the strategy for drug supply for hepatitis C patients in Moscow. Problemy sotsial’noy gigieny, zdravookhraneniya i istorii meditsiny. 2020; 28(S2): 1154–61. https://doi.org/10.32687/0869-866X-2020-28-s2-1154-1161 (in Russian)
  26. State report «On the state of sanitary and epidemiological welfare of the population in the city of Moscow in 2019». Moscow; 2020. (in Russian)
  27. Vademecum. Moscow will fully switch to interferon-free hepatitis C treatment regimens in 2020. Available at: https://vademec.ru/news/2019/07/17/moskva-v-2020-godu-polnostyu-pereydet-na-bezinterferonovye-skhemy-terapii-gepatita-s/ (in Russian)
  28. Nurmukhametova E.A. Providing specialized medical care for patients with chronic viral hepatitis C in Moscow. Report in the framework of the XVII Assembly «Health of Moscow». Moskovskaya meditsina. 2018; (S): 93. (in Russian)
  29. Pimenov N.N., Komarova S.V., Karandashova I.V., Tsapkova N.N., Volchkova E.V., Chulanov V.P. Hepatitis С and its outcomes in Russia: analysis of incidence, prevalence and mortality rates before the start of the programme of infection elimination. Infektsionnye bolezni. 2018; 16(3): 37–45. https://doi.org/10.20953/1729-9225-2018-3-37-45 (in Russian)
  30. Lawitz E., Poordad F., Gutierrez J.A., Wells J.T., Landaverde C.E., Evans B., et al. Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial. Hepatology. 2017; 65(2): 439–50. https://doi.org/10.1002/hep.28877
  31. EASL recommendations on treatment of hepatitis C 2018. J. Hepatol. 2018; 69(2): 461–511. https://doi.org/10.1016/j.jhep.2018.03.026

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Kornilova E.B., Hołownia-Voloskova M.E., Ar’Kova E.S., Roslik D.A., Luchinin E.A., Zavyalov A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ:  ПИ № ФС77-50668 от 13.07.2012 г.